Biomarkers in Breast Cancer: An Old Story with a New End

Author:

Neves Rebello Alves Lyvia12ORCID,Dummer Meira Débora12,Poppe Merigueti Luiza1,Correia Casotti Matheus12ORCID,do Prado Ventorim Diego3,Ferreira Figueiredo Almeida Jucimara1,Pereira de Sousa Valdemir12,Cindra Sant’Ana Marllon1ORCID,Gonçalves Coutinho da Cruz Rahna1,Santos Louro Luana4,Mendonça Santana Gabriel4,Erik Santos Louro Thomas5,Evangelista Salazar Rhana12,Ribeiro Campos da Silva Danielle12,Stefani Siqueira Zetum Aléxia12,Silva dos Reis Trabach Raquel1,Imbroisi Valle Errera Flávia12,de Paula Flávia12,de Vargas Wolfgramm dos Santos Eldamária12,Fagundes de Carvalho Elizeu6,Drumond Louro Iúri12ORCID

Affiliation:

1. Núcleo de Genética Humana e Molecular, Departamento de Ciências Biológicas, Universidade Federal do Espírito Santo (UFES), Vitória 29075-910, ES, Brazil

2. Programa de Pós-Graduação em Biotecnologia, Universidade Federal do Espírito Santo, Vitória 29047-105, ES, Brazil

3. Instituto Federal de Educação, Ciência e Tecnologia do Espírito Santo (Ifes), Cariacica 29150-410, ES, Brazil

4. Centro de Ciências da Saúde, Curso de Medicina, Universidade Federal do Espírito Santo (UFES), Vitória 29090-040, ES, Brazil

5. Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória (EMESCAM), Vitória 29027-502, ES, Brazil

6. Instituto de Biologia Roberto Alcântara Gomes (IBRAG), Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro 20551-030, RJ, Brazil

Abstract

Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease and the leading cause of cancer mortality in women. Advances in molecular technologies allowed for the identification of new and more specifics biomarkers for breast cancer diagnosis, prognosis, and risk prediction, enabling personalized treatments, improving therapy, and preventing overtreatment, undertreatment, and incorrect treatment. Several breast cancer biomarkers have been identified and, along with traditional biomarkers, they can assist physicians throughout treatment plan and increase therapy success. Despite the need of more data to improve specificity and determine the real clinical utility of some biomarkers, others are already established and can be used as a guide to make treatment decisions. In this review, we summarize the available traditional, novel, and potential biomarkers while also including gene expression profiles, breast cancer single-cell and polyploid giant cancer cells. We hope to help physicians understand tumor specific characteristics and support decision-making in patient-personalized clinical management, consequently improving treatment outcome.

Publisher

MDPI AG

Subject

Genetics (clinical),Genetics

Reference236 articles.

1. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches;Schick;Breast Cancer,2021

2. Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer;Stickeler;Breast Care,2011

3. Breast cancer;Harbeck;Nat. Rev. Dis. Primers,2019

4. Breast cancer: Biology, biomarkers, and treatments;Barzaman;Int. Immunopharmacol.,2020

5. Predictive and prognostic molecular markers for cancer medicine;Mehta;Ther. Adv. Med. Oncol.,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3